At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 641 enrolled
Drug / intervention
GSK3511294 (Depemokimab)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744
In Brief
A Phase 3 clinical trial evaluating GSK3511294 (Depemokimab) for Asthma. Completed, enrolled 641 participants across 137 sites in 14 countries.
Detailed Summary
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesAustralia, Canada, China, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Spain, Taiwan, United Kingdom, United States
CollaboratorsIQVIA Pty Ltd
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionMay 2025
TodayJul 2026
First PostedFeb 17, 2022
Enrollment StartMar 1, 2022
Primary CompletionMay 19, 2025
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 4.4 years ago
Interventions
GSK3511294 (Depemokimab)biological
GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe.